Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seagen Aims To Make Tukysa First Drug For HER2-Positive Colorectal Cancer

Executive Summary

The Phase II MOUNTAINEER trial showed a benefit for patients with HER2-positive metastatic colorectal cancer treated with the tyrosine kinase inhibitor in combination with trastuzumab.

You may also be interested in...



Seagen Taps Epstein As New CEO After A Tumultuous Year

Former Novartis executive and venture capitalist David Epstein will step in to lead Seagen after its founder resigned in a scandal and amid M&A speculation.

Merck & Co Closing In On Seagen Acquisition

Merck is closing in on the acquisition of the antibody drug conjugate specialists which would help the pharma giant consolidate its presence in oncology.

Merck & Co Could Be Plotting $30bn Bid For Seagen

A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel